Table 3.
The key parameter of clinical trials using transplantation of mesenchymal stem cells in treating ischemic stroke
|
Ref.
|
Country
|
Design
|
Type
|
Route
|
MSCs source
|
Sample size (cases)
|
Dose
|
How long
|
Follow-up
|
|
|
Auto or allo
|
MSCs
|
Control
|
(Mean)
|
(Mean)
|
(Mean)
|
|||||
| Savitz et al[137], 2011 | America | Non-RCT | Acute | IV | BM/Auto | 10 | NA | 100 × 106 | 1-3 d | 0.5 yr |
| Lee et al[138], 2010 | South Korea | RCT | Acute | IV | PIC/Auto | 16 | 36 | 50 × 106 | 1 wk | 5 yr |
| Bhasin et al[151], 2011 | India | Non-RCT | Chronic | IV | BM/Auto | 4 | 5 | 50-60 × 106 | 8 wk | 24 wk |
| Bhasin et al[139], 2012 | India | Non-RCT | Chronic | IV | PIC/Auto | 12 | 12 | 50-60 × 106 | 3-24 mo | 0.5 yr |
| Bhasin et al[140], 2016 | India | Non-RCT | Chronic | IV | PIC/Auto | 20 | 20 | 50-60 × 106 | 3-24 mo | 0.5 yr |
| Chen et al[141], 2014 | China | RCT | Chronic | Stereotactic | PB/Auto | 15 | 15 | 3-8 × 106 | 0.5-5 yr | 1 yr |
| Jiang et al[149], 2013 | China | Non-RCT | NA | Catheterization | UC/Allo | 3 | NA | 20 × 106 | 11-22 d | 0.5 yr |
| Laskowitz et al[14], 2018 | America | RCT | Acute | IV | UC/Allo | 10 | 10 | 3.34 × 106 | 3-9 d | 1 yr |
| Levy et al[142], 2019 | America | Non-RCT | Chronic | IV | NA/Allo | 15 and 20 | NA | NA | NA | 1 yr |
| Moniche et al[143], 2012 | Spain | RCT | Subacute | IA | PIC/Auto | 10 | 10 | 159 × 106 | 5-9 d | 0.5 yr |
| Prasad et al[144], 2014 | India | RCT | Subacute | IV | PIC/Auto | 60 | 60 | 280.5 × 106 | 1-4 mo | 0.5 yr |
| Suárez-Monteagudo et al[150], 2009 | Cuba | Non-RCT | NA | IV | BM/Auto | 3 | NA | NA | NA | 3 M |
| Vahidy et al[145], 2019 | America | RCT | Acute | IV | BM/Auto | 25 | 30 | NA | 1-3 d | 2 yr |
| Zhang et al[146], 2019 | China | Non-RCT | NA | Stereotactic | FSC/Allo | 9 | NA | NA | 494 d | 2 yr |
| Díez-Tejedor et al[148], 2014 | Spain | RCT | Acute | IV | Adipose/Allo | 20 | 20 | NA | 0.5 mo | 2 yr |
| Feng et al[147], 2014 | China | NA | Subacute | Stereotactic | UC/Allo | 50 | 50 | 100 × 106 | 0.5-1 mo | 0.25 yr |
| Jaillard et al[153], 2020 | France | RCT | Subacute | IV | BM/Allo | 16 | 15 | 100-300 × 106 | 3 wk | 24 mo |
| De Keyser[152], 2005 | South Korea | Non-RCT | Acute | IV | BM/Allo | 5 | 25 | 50 × 106 | 4-9 wk | 12 mo |
NA: Not available; MSCs: Mesenchymal stem cells; Auto: Autologous; Allo: Allogenicr; PIC: Posterior iliac crest; IV: Intravenous; IA: Intraarterial; RCT: Randomized controlled trial; UC: Umbilical cord; BM: Bone marrow; FSC: Fetal spinal cord; PB: Peripheral blood.